Human milk oligosaccharides inhibit rotavirus infectivity in vitro and in acutely infected piglets

Br J Nutr. 2013 Oct;110(7):1233-42. doi: 10.1017/S0007114513000391. Epub 2013 Feb 26.

Abstract

Human milk (HM) is rich in oligosaccharides (HMO) that exert prebiotic and anti-infective activities. HM feeding reduces the incidence of rotavirus (RV) infection in infants. Herein, the anti-RV activity of oligosaccharides was tested in an established in vitro system for assessing cellular binding and viral infectivity/replication, and also tested in a newly developed, acute RV infection, in situ piglet model. For the in vitro work, crude HMO isolated from pooled HM, neutral HMO (lacto-N-neotetraose, LNnT; 2'-fucosyllactose) and acidic HMO (aHMO, '-sialyllactose, 3'-SL; -sialyllactose, -SL) were tested against the porcine OSU strain and human RV Wa strain. The RV Wa strain was not inhibited by any oligosaccharides. However, the RV OSU strain infectivity was dose-dependently inhibited by sialic acid (SA)-containing HMO. 3'-SL and 6'-SL concordantly inhibited (125)I-radiolabelled RV cellular binding and infectivity/replication. For the in situ study, a midline laparotomy was performed on 21-d-old formula-fed piglets and six 10 cm loops of ileum were isolated in situ. Briefly, 2 mg/ml of LNnT, aHMO mixture (40% 6'-SL/10 % 3'-SL/50 % SA) or media with or without the RV OSU strain (1 x 10(7) focus-forming units)were injected into the loops and maintained for 6 h. The loops treated with HMO treatments þ RV had lower RV replication, as assessed by non-structural protein-4 (NSP4) mRNA expression, than RV-treated loops alone. In conclusion, SA-containing HMO inhibited RV infectivity in vitro; however, both neutral HMO and SA with aHMO decreased NSP4 replication during acute RV infection in situ.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Animals
  • Diet
  • Dietary Carbohydrates / pharmacology
  • Dietary Carbohydrates / therapeutic use*
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Humans
  • Lactose / analogs & derivatives
  • Lactose / pharmacology
  • Lactose / therapeutic use
  • Milk, Human / chemistry*
  • N-Acetylneuraminic Acid / pharmacology
  • N-Acetylneuraminic Acid / therapeutic use
  • Oligosaccharides / pharmacology
  • Oligosaccharides / therapeutic use*
  • RNA, Messenger / metabolism
  • Rotavirus / classification
  • Rotavirus / drug effects*
  • Rotavirus / pathogenicity
  • Rotavirus Infections / prevention & control*
  • Rotavirus Infections / virology
  • Species Specificity
  • Swine
  • Viral Nonstructural Proteins / genetics
  • Viral Nonstructural Proteins / metabolism
  • Virus Attachment / drug effects*
  • Virus Replication / drug effects*

Substances

  • 3'-sialyllactose
  • 6'-sialyllactose
  • Dietary Carbohydrates
  • Oligosaccharides
  • RNA, Messenger
  • Viral Nonstructural Proteins
  • N-Acetylneuraminic Acid
  • Lactose